Excess matrix accumulation in scleroderma is caused partly by differential regulation of stromelysin and TIMP-1 synthesis.

[1]  J. Seibold,et al.  Endothelial and fibroblastic activation in scleroderma. The myth of the "uninvolved skin". , 2010, Arthritis and rheumatism.

[2]  G. Raghu,et al.  Production of collagenase and tissue inhibitor of metalloproteinases by fibroblasts derived from normal and fibrotic human lungs. , 1992, Chest.

[3]  L. Matrisian.  The matrix‐degrading metalloproteinases , 1992, Journal of neuro-oncology.

[4]  M. Heckmann,et al.  Steady-state mRNA levels of collagens I, III, fibronectin, and collagenase in skin biopsies of systemic sclerosis patients. , 1991, The Journal of investigative dermatology.

[5]  M. Cockett,et al.  Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP). , 1991, The Biochemical journal.

[6]  E. Leroy,et al.  The pathogenesis of scleroderma (systemic sclerosis, SSc). , 1991, Clinical and experimental rheumatology.

[7]  J. Wrana,et al.  Independent regulation of collagenase, 72-kDa progelatinase, and metalloendoproteinase inhibitor expression in human fibroblasts by transforming growth factor-beta. , 1989, The Journal of biological chemistry.

[8]  J. Rosenbloom,et al.  Transforming growth factor beta (TGF beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts. , 1987, The Biochemical journal.

[9]  J. Heath,et al.  Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. , 1987, The EMBO journal.

[10]  J. Rosenbloom,et al.  Co-ordinate increase in the expression of type I and type III collagen genes in progressive systemic sclerosis fibroblasts. , 1986, The Biochemical journal.

[11]  M. Sporn,et al.  Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[12]  L. Matrisian,et al.  Isolation of the oncogene and epidermal growth factor-induced transin gene: complex control in rat fibroblasts , 1986, Molecular and cellular biology.

[13]  G. Rodnan,et al.  Progressive systemic sclerosis (PSS, scleroderma) dermal fibroblasts synthesize increased amounts of glycosaminoglycan. , 1983, The Journal of laboratory and clinical medicine.

[14]  R. Timpl,et al.  Variability in collagen and fibronectin synthesis by scleroderma fibroblasts in primary culture. , 1981, The Journal of investigative dermatology.

[15]  R. Timpl,et al.  Immunofluorescence analysis of collagen, fibronectin, and basement membrane protein in scleroderma skin. , 1980, The Journal of investigative dermatology.

[16]  A. Eisen,et al.  Scleroderma: increased biosynthesis of triple-helical type I and type III procollagens associated with unaltered expression of collagenase by skin fibroblasts in culture. , 1979, The Journal of clinical investigation.

[17]  A. H. Brady,et al.  Collagenase in scleroderma. , 1975, The Journal of clinical investigation.

[18]  E. Leroy.  CONNECTIVE TISSUE SYNTHESIS BY SCLERODERMA SKIN FIBROBLASTS IN CELL CULTURE , 1972, The Journal of experimental medicine.

[19]  T. Krieg,et al.  Control of fibrosis in systemic scleroderma. , 1993, The Journal of investigative dermatology.

[20]  H. Birkedal‐Hansen,et al.  Matrix metalloproteinases: a review. , 1993, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

[21]  R. Gray,et al.  Inhibition of alkali-induced corneal ulceration and perforation by a thiol peptide. , 1990, Investigative ophthalmology & visual science.

[22]  A. Docherty,et al.  Molecular studies on the connective tissue metalloproteinases and their inhibitor TIMP , 1988 .